Bulletin
Investor Alert

Cerecor Inc.

NAS: CERC

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Cerecor Inc.

After Hours

 --Quotes are delayed by 20 min

Jan 22, 2021, 7:59 p.m.

CERC
/zigman2/quotes/201368871/composite

$

3.47

Change

-0.03 -0.86%

Volume

Volume 53,459

Quotes are delayed by 20 min

/zigman2/quotes/201368871/composite

Previous close

$ 3.09

$ 3.50

Change

+0.41 +13.27%

Day low

Day high

$3.05

$3.51

Open

52 week low

52 week high

$1.52

$4.73

Open

Company Description

Cerecor, Inc. engages in the development and commercialization of treatments for rare pediatric and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation. The company...

Cerecor, Inc. engages in the development and commercialization of treatments for rare pediatric and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Valuation

Price to Sales Ratio

34.24

Price to Book Ratio

11.40

Enterprise Value to Sales

32.76

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

375,020.00

Income Per Employee

-903,931.00

Receivables Turnover

0.97

Total Asset Turnover

0.13

Liquidity

Current Ratio

1.46

Quick Ratio

1.46

Cash Ratio

0.93

Profitability

Gross Margin

63.08

Operating Margin

-281.37

Pretax Margin

-236.88

Net Margin

-241.04

Return on Assets

-30.57

Return on Equity

-77.66

Return on Total Capital

-64.88

Return on Invested Capital

-56.75

Capital Structure

Total Debt to Total Equity

6.04

Total Debt to Total Capital

5.69

Total Debt to Total Assets

3.51

Long-Term Debt to Equity

5.30

Long-Term Debt to Total Capital

4.99

Officers and Executives

Name Age Officer Since Title
Mr. Michael F. Cola 59 2020 Chief Executive Officer & Director
Mr. Christopher Sullivan 35 2018 Vice President-Finance
Dr. Garry Arthur Neil 65 2020 Chief Medical Officer
Dr. Younok Dumortier Shin - - Chief Technology Officer
Dr. H. Jeffrey Wilkins 57 2020 Chief Development Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/10/2020 Garry Arthur Neil
Chief Scientific Officer 		3,599   Acquisition at $2.28 per share. 8,205
12/10/2020 James A. Harrell
Chief Commercial Officer 		171   Acquisition at $2.28 per share. 389
12/10/2020 Christopher Sullivan
Interim CFO 		5,095   Acquisition at $2.28 per share. 11,616
12/03/2020 Armistice Capital LLC
Director 		0   Acquisition at $0 per share. 0
12/03/2020 Armistice Capital LLC
Director 		20,000   Acquisition at $2.44 per share. 48,800
11/25/2020 Armistice Capital LLC
Director 		0   Acquisition at $0 per share. 0
11/25/2020 Armistice Capital LLC
Director 		15,000   Acquisition at $2.39 per share. 35,850
11/24/2020 Armistice Capital LLC
Director 		0   Acquisition at $0 per share. 0
11/24/2020 Armistice Capital LLC
Director 		47,733   Acquisition at $2.4 per share. 114,559
11/23/2020 Armistice Capital LLC
Director 		0   Acquisition at $0 per share. 0
11/23/2020 Armistice Capital LLC
Director 		37,267   Acquisition at $2.32 per share. 86,459
09/04/2020 Armistice Capital LLC
Director 		0   Acquisition at $0 per share. 0
09/04/2020 Armistice Capital LLC
Director 		100,000   Acquisition at $2.2 per share. 220,000
06/10/2020 Garry Arthur Neil
Chief Scientific Officer 		1,799   Acquisition at $2.28 per share. 4,101
06/10/2020 James A. Harrell
Chief Commercial Officer 		6,391   Acquisition at $2.28 per share. 14,571
06/10/2020 Christopher Sullivan
Interim CFO 		2,954   Acquisition at $2.28 per share. 6,735
06/09/2020 Armistice Capital LLC
Director 		267,806   Acquisition at $2.52 per share. 674,871
06/09/2020 Armistice Capital LLC
Director 		0   Acquisition at $0 per share. 0
06/09/2020 Armistice Capital LLC
Director 		1,753,680   Acquisition at $2.5 per share. 4,384,200
06/09/2020 Michael F. Cola
Chief Executive Officer; Director 		100,000   Acquisition at $2.5 per share. 250,000
06/09/2020 Michael F. Cola
Chief Executive Officer; Director 		100,000   Acquisition at $2.5 per share. 250,000
06/09/2020 James A. Harrell
Chief Commercial Officer 		10,000   Acquisition at $2.5 per share. 25,000
06/08/2020 Joseph M. Miller
Director 		4,472   Derivative/Non-derivative trans. at $3.22 per share. 14,399
04/09/2020 Simon C. Pedder
Executive Chairman of the Bd; Director 		20,901   Derivative/Non-derivative trans. at $2.57 per share. 53,715
/news/latest/company/us/cerc

MarketWatch News on CERC

  1. Big Stock Buys at Winnebago, National CineMedia

    8:40 p.m. March 27, 2020

    - Barron's Online

  2. Cerecor started at outperform with $11 stock price target at Oppenheimer

    8:52 a.m. Jan. 10, 2020

    - Tomi Kilgore

  4. Starboard Value Urges Zayo Group to Sell Itself

    12:10 a.m. March 16, 2019

    - Barron's Online

  5. There’s Value in Damaged Papa John’s Pizza

    7:00 p.m. Oct. 5, 2018

    - Barron's Online

  7. Cerecor Inc. shares drop 37% after midstage trial failure

    8:14 a.m. Dec. 5, 2016

    - Emma Court

  8. Cerecor's stock extends slide, plunges 37% premarket after failed drug trial

    8:09 a.m. Dec. 5, 2016

    - Tomi Kilgore

  9. Cerecor says mid-stage trial of treatment for nicotine withdrawal missed its target

    8:05 a.m. Dec. 5, 2016

    - Ciara Linnane

  10. Cerecor's stock tumbles 14% premarket after drug trial fails to meet primary endpoint

    8:05 a.m. Dec. 5, 2016

    - Tomi Kilgore

  11. Cerecor's stock on track to open at all-time low

    8:06 a.m. Dec. 5, 2016

    - Tomi Kilgore

/news/nonmarketwatch/company/us/cerc

Other News on CERC

  2. Cerecor prices $36.4M stock and warrants offering

    11:34 p.m. Jan. 7, 2021

    - Seeking Alpha

  3. Cerecor slumps 12% on stock and pre-funded warrants offering

    4:16 p.m. Jan. 7, 2021

    - Seeking Alpha

  4. Cerecor gains on CERC-002 data in mid-stage COVID-19 study

    10:22 a.m. Jan. 5, 2021

    - Seeking Alpha

  5. CHU, CHL, FUBO and SKLZ among premarket gainers

    8:27 a.m. Jan. 5, 2021

    - Seeking Alpha

  9. CLDR, DOMO, PD and UMC among premarket gainers

    8:26 a.m. Dec. 4, 2020

    - Seeking Alpha

  15. 10-Q: CERECOR INC.

    6:42 a.m. Aug. 6, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  17. OPK, NBEV among premarket gainers

    7:23 a.m. July 21, 2020

    - Seeking Alpha

  18. Enrollment underway in Cerecor CERC-002 study for COVID-19 ARDS

    6:29 a.m. July 21, 2020

    - Seeking Alpha

  19. Largest Insider Trades of the Week

    8:42 a.m. June 12, 2020

    - GuruFocus.com

  21. Loading more headlines...

At a Glance

Cerecor, Inc.

540 Gaither Road

Suite 400

Rockville, Maryland 20850

Phone

1 4105228707

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

View SEC Filings

Revenue

$6.75M

Net Income

$-16.27M

Employees

18.00

Annual Report for CERC

/news/pressrelease/company/us/cerc

Press Releases on CERC

  11. Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors

    6:00 a.m. Oct. 12, 2020

    - GlobeNewswire

  12. Cerecor to Present at Upcoming Investor Conferences

    6:00 a.m. Sept. 10, 2020

    - GlobeNewswire

  13. Stocks Which Saw Increased Insider Transactions: $QRHC $CERC $APEN

    7:29 a.m. Sept. 1, 2020

    - The Market Signal

  21. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.